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The aim of this study was to evaluate the usefulness of EGFR mutation status in serum DNA as a means of predicting a benefit from
gefitinib (IRESSA) therapy in Japanese patients with non-small cell lung cancer (NSCLC). We obtained pairs of tumour and serum
samples from 42 patients treated with gefitinib. EGFR mutation status was determined by a direct sequencing method and by
Scorpion Amplification Refractory Mutation System (ARMS) technology. EGFR mutations were detected in the tumour samples of
eight patients and in the serum samples of seven patients. EGFR mutation status in the tumours and serum samples was consistent in
39 (92.9%) of the 42 pairs. EGFR mutations were strong correlations between both EGFR mutation status in the tumour samples and
serum samples and objective response to gefitinib (Po0.001). Median progression-free survival time was significantly longer in the
patients with EGFR mutations than in the patients without EGFR mutations (194 vs 55 days, P¼0.016, in tumour samples; 174 vs 58
days, P¼0.044, in serum samples). The results suggest that it is feasible to use serum DNA to detect EGFR mutation, and that it’s
potential as a predictor of response to, and survival on gefitinib is worthy of further evaluation.
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Lung cancer is a major cause of cancer-related mortality worldwide
and is expected to remain a major health problem for the
foreseeable future (Parkin et al, 2005). Most patients have
advanced disease at the time of diagnosis. Initial therapy for
advanced non-small cell lung cancer (NSCLC) is typically systemic
chemotherapy with a two-drug combination regimen, which often
includes a platinum agent, but the median survival of patients
treated with such regimens has ranged from only 8 to 10 months
(Breathnach et al, 2001; Kelly et al, 2001; Schiller et al, 2002). Little
improvement in the efficacy of chemotherapy has been made in the
last 20 years. A recent report shows that the addition of
bevacizumab, a monoclonal antibody against vascular endothelial
growth factor, to paclitaxel plus carboplatin in patients with
advanced NSCLC has a significant survival benefit, and the median
survival was 12.3 months, as compared with 10.3 months in the
chemotherapy-alone group (Sandler et al, 2006).
Targeting epidermal growth factor receptor (EGFR) is an
appealing strategy for the treatment of NSCLC, because EGFR
has been found to be expressed, sometimes strongly, in NSCLC
(Franklin et al, 2002). Gefitinib (‘Iressa’, AstraZeneca) is a small
molecule and selective EGFR tyrosine kinase inhibitor (EGFR-TKI)
that has shown antitumour activity in NSCLC patients as a single
agent in phase II and III trials (Fukuoka et al, 2003; Thatcher et al,
2005). An association between mutations in EGFR tyrosine kinase
sites in NSCLC patients and hyper-responsiveness to gefitinib has
recently been reported (Lynch et al, 2004; Paez et al, 2004). The
mutations consisted of small in-frame deletions or substitutions
clustered around the ATP-binding site in exons 18–21 of EGFR.
Some investigators subsequently found that EGFR mutations are
one of the strong determinants of tumour response to EGFR
tyrosine kinase inhibitors (Pao et al, 2004; Han et al, 2005;
Shigematsu et al, 2005). The mutation status could be evaluated
stably in studies that used surgical tissues to detect the EGFR
mutations, but most patients who require gefitinib therapy already
have advanced disease at the time of diagnosis and therefore are
not operated on. It is difficult to obtain sufficient tumour DNA
from non-surgical tissue samples, for example, those derived from
bronchoscopy that allow detection of EGFR mutations by direct
sequencing. Actually, translational research in patients with
advanced NSCLC in whom gefitinib therapy recommended has
been limited by the scarcity of available tumour biopsy tissue, and
tumour samples for genetic research were only available for 12.7
and 44.5%, respectively, of patients enrolled in two large phase III
clinical studies with EGFR-TKIs (Tsao et al, 2005; Hirsch et al,
2006). It is therefore important to have sensitive methods for
detecting EGFR mutations from DNA derived from non-surgical
tissue specimens.
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sIt is well known that the concentration of circulating DNA in
plasma or serum has been found to be higher in cancer patients
than in cancer-free control subjects, and that significantly higher
DNA levels are found in the serum of patients with metastatic
disease (Leon et al, 1977; Jahr et al, 2001; Sozzi et al, 2003). The
tumour-derived DNA in serum may have been released by a
tumour mass that has undergone cell necrosis or tumour cells
lysis, or by circulating tumour cells, resulting in a very elevated
serum DNA concentration. Some investigators have shown that
testing for DNA alterations in peripheral blood has great potential,
especially for early detection and diagnosis and for monitoring for
a relapse during follow-up (Chen et al, 1996; Nawroz et al, 1996;
Sozzi et al, 1999, 2001; Cuda et al, 2000; Nunes et al, 2001). The
same alterations which mean mutations, methylation, and loss of
heterozygosity, in genomic DNA have been observed in DNA from
both tumour cells in resected and biopsy specimens, and from
serum samples in patients with various types of tumours,
including NSCLC (Sanchez-Cespedes et al, 1998; Esteller et al,
1999). Some studies have even reported that genetic aberrations in
serum DNA modulate survival in NSCLC patients treated with
chemotherapy. Their authors have proposed that the assay used in
their studies may obviate the need for tumour tissue analysis
(Ramirez et al, 2005; de las Penas et al, 2006). Serum samples can
be obtained safely, with the option of repeat sampling from all
NSCLC patients regardless of patient characteristics. The detection
of EGFR mutations in serum provides a unique and potentially
valuable tumour marker for prediction of response and prognosis.
We have previously reported the feasibility of detecting EGFR
mutations in serum DNA using the Scorpion Amplification
Refractory Mutation System (ARMS) method (Kimura et al,
2006). The Scorpion ARMS method is one of the most sensitive
and fastest methods for specific detection of mutations in DNA
(Newton et al, 1989; Whitcombe et al, 1999). Although EGFR
mutations were detectable by both PCR direct sequencing, which
has generally been used to detect the mutations and the Scorpion
ARMS method, mutation status determined with Scorpion ARMS
predicted response to gefitinib in our study (Kimura et al, 2006).
Since the previous study did not clarify the feasibility of using
serum DNA as a practical source for detection of EGFR mutations,
in the present study, we sought to demonstrate that EGFR
mutation status determined in serum DNA is the same as in
actual tumour samples.
The aim of this study was (1) to determine whether the EGFR
mutations in tumour tissue and serum samples from advanced
NSCLC patients are the same, and (2) to identify whether there is a
correlation between EGFR mutation status detected in serum DNA
and both response to gefitinib and survival benefit from gefitinib.
PATIENTS AND METHODS
Patients
The subjects were patients with advanced NSCLC in whom
gefitinib therapy was started between July 2002 and February
2006. All patients were treated with gefitinib alone, and 14 patients
were treated with gefitinib as initial therapy. The others were
treated with gefitinib as second- or third-line therapy. The
diagnosis of NSCLC was based on the histological or cytological
findings, and the histological type was determined according to
WHO criteria (Travis et al, 1999). Patients’ records consisted of
age, gender, smoking habit, and histological tumour type. Patients
were divided into three groups according to their smoking status:
never-smokers (o100 cigarettes per lifetime), former smokers
(X100 cigarettes per lifetime, but quit 1 year before diagnosis),
and current smokers (X100 cigarettes per lifetime). The response
to gefitinib was evaluated in accordance with the ‘Response
Evaluation Criteria in Solid Tumours (RECIST)’ guidelines
(Therasse et al, 2000). This study was approved by the Institutional
Review Board of Kanazawa University Hospital. Written informed
consent was obtained from all participants. No research results
were entered into the patient’s records or released to the patient or
the patient’s physician.
Tissue preparation and DNA extraction
Tumour specimens were obtained at diagnosis and analysed
retrospectively. Twenty-eight tumour samples were collected from
the primary cancer (19 via transbronchial lung biopsy, 2 via
percutaneous lung biopsy, and 7 surgical specimens). Fourteen
tumour samples were from metastatic sites (three from bone, eight
lymph nodes, one brain, and one small bowel). All specimens were
examined histologically to confirm the diagnosis of NSCLC. The
tumour specimens obtained were fixed in formalin and embedded
in paraffin wax. Serial sections containing representative malig-
nant cells were deparaffinised in xylene washes and dehydrated in
100% ethanol. DNA was extracted from five serial 10-mm thick
sections by using the QIAamp DNA Mini kit (Qiagen, Hilden,
Germany) according to the protocol described in the manufac-
turer’s instructions. The DNA obtained was eluted in 50mlo f
buffer AE, and the concentration and purity of the extracted DNA
were assessed by spectrophotometry. The extracted DNA was
stored at  201C until used.
Blood sample collection and DNA extraction
Blood samples were collected before the start of gefitinib therapy.
The volume of each blood sample was 4ml. Serum was separated
within 2h from the sample collection and stored at –801C until
used. Serum DNA was extracted and purified by using a Qiamp
Blood Kit (Qiagen), with the following protocol modifications. One
column was used repeatedly until the whole sample had been
processed. The resulting DNA was eluted in 50ml of sterile bi-
distilled buffer. The concentration and purity of the extracted DNA
were determined by spectrophotometry. The extracted DNA was
stored at –201C until used.
Direct sequencing for detection of EGFR mutations
EGFR mutations in exons 18, 19, and 21 were detected by PCR-
based direct sequencing. PCR amplification was performed in
10ng of genomic DNA using the TaKaRa Ex Taqt Hot Start
Version kit (TaKaRa, Tokyo, Japan). The primers (forward and
reverse) were: exon 18 (50-CCTTGTCTCTGTGTTCTTGT-30 and 50-
CTGCGGCCCAGCCCAGAGGC-30), exon 19 (50-CATGTGGCAC
CATCTCACA-30 and 50-CCACACAGCAAAGCAGAA AC-30), and
exon 21 (50-CAGGGTCTTCTCTGTTTCAG-30 and 50-TAAAGC
CACCTCCTTACTTT-30). DNA was amplified for 35 cycles at
951C for 30s, 611C for 30s, and 721C for 60s followed by 7min of
extension at 721C. Sequencing was performed with a 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA), and the
results were analysed with Sequencer 3.11 software (Applied
Biosystems) to compare variations. The sequences were compared
with the GenBank human sequence for EGFR (accession number
AF288738).
Scorpion ARMS for detection of E746_A750del and L858R
An EGFR Scorpion Kit (DxS Ltd, Manchester, UK), which
combines two technologies, namely ARMS and Scorpion was to
detect mutations in real-time PCR as described previously (Kimura
et al, 2006). Four scorpion primers for detection of E746_A750del,
L858R, and the wild type in both exons 19 and 21 were designed
and synthesised by DxS Ltd. All reactions were performed in 25ml
volumes using 1ml of template DNA, 7.5ml of reaction buffer mix,
0.6ml of Primer mix and 0.1ml of Taq polymerase. All reagents are
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sincluded in the kit. Real-time PCR was carried out by using
SmartCycler
s II (Cepheid, Sunnyvale, CA, USA) under the
following conditions: initial denaturation at 951C for 10min, 50
cycles of 951C for 30s, 621C for 60s with fluorescence reading (set
to FAM, which allows optical excitation at 480nm and measure-
ment at 520nm) at the end of each cycle. Data analysis was
performed with Cepheid SmartCycler software (version 1.2b). The
cycle threshold (Ct) was defined as the cycle at the highest peak of
the second-derivative curve, which represented the point of
maximum curvature of the growth curve. Both Ct and maximum
fluorescence (Fl) were used to interpret the results. Positive results
were defined as follows: Ct p45 and Fl X50. These analyses were
performed in duplicate for each sample and reviewed by two
investigators blinded to any clinical information.
Statistical analyses
Patient characteristics, including gender, tumour histology, smok-
ing habit, and response to gefitinib, were tabulated according to
mutation status. Fisher’s exact test was used to test for associations
between the presence of EGFR mutations and the patients’
characteristics. Overall survival (OS) and progression-free survival
(PFS) according to EGFR mutation status were estimated by the
Kaplan–Meier method, and compared using the two-sided log-
rank test. Overall survival was defined as the interval between the
start of gefitinib therapy and death from any cause; patients known
to be still alive at the time of the analysis were censored at the time
of their last follow-up. Progression-free survival was defined as the
interval between the start of gefitinib therapy and the first
manifestation of progressive disease (PD) or death from any
cause; patients known to be alive and without PD at the time of
analysis were censored at the time of their last follow-up.
RESULTS
Patient’s characteristics
Forty-two patients were enrolled in this study (Table 1). This study
covered a long period. There are two reasons why it took 4 years to
assemble the 42 patients enrolled. One is that this study was
carried out in Kanazawa University Hospital alone, and was not a
multicentre study. The other is that not all patients with NSCLC at
the hospital during that period were enrolled in this study, because
some were enrolled in other trials or the patients refused. Their
median age was 58 years (range, 40–81 years), and there were 14
females (33.3%) and 14 never-smokers (33.3%). The histological
and/or cytological diagnosis was adenocarcinoma in 31 patients
(73.8%), squamous cell carcinoma in 7 (16.7%), and large-cell
carcinoma in 4 (9.5%). The results for response to gefitinib showed
that 10 patients (23.8%) had a partial response (PR) and 14
(33.3%) had stable disease (SD). The other 18 patients (42.9%) had
PD. Serum DNA was extracted in all 42 samples at a median
concentration of 62.0ngml
 1 (range, 0–342.8). The concentra-
tions in 10 samples were below the minimum concentration
detectable.
EGFR mutation status detected
Direct sequencing of PCR products from tumour tissues of all
patients allowed their mutation status to be determined. Both
direct sequencing and Scorpion ARMS allowed mutation status to
be determined in the serum samples of all patients. As summarised
in Table 2, mutations were identified in 9 (21.4%) of the 42
patients. Mutations in eight patients were detected in tumour
samples and seven in serum samples. Five mutations were deletion
mutations located in exon 19 (E746_A750del in four and
L747_T751del in one). Four mutations were substitution mutations
located in exon 21 (L858R), and one was a substitution mutation
located in exon 18 (V689L). One patient had double substitution
mutations (V689L and L858R). The E746_A750 deletion and L858R
substitution mutation were the most common (8 out of 9, 88.9%),
and both are well-known hot spot mutations described previously
(Kosaka et al, 2004; Han et al, 2005). There were no T790M
mutations identified by direct sequencing on tumour samples or
serum samples. Of the nine patients with mutations, six (66.7%)
were never-smokers, and five (55.6%) were female patients. Almost
all of the patients with mutations had adenocarcinoma (8 out of 9,
88.9%).
Sensitivity and specificity of detection in serum DNA
In six of the patients, the same EGFR mutation was detected in
both the tumour sample and the serum sample. There were no
EGFR mutations detected in either the tumour sample or serum
sample from 33 of the patients. EGFR mutation status was
consistent in 39 (92.9%) of the 42 of the pairs (Table 3). In two
patients the tumour samples was positive for an EGFR mutation
and the serum sample was negative. The concentrations of serum
DNA in the two patients were below the minimum level of
detection by spectrophotometry. In one patient, the serum sample
was positive for an EGFR mutation and the tumour sample was
negative. The tumour sample that contained no mutations from
the patient whose serum was positive for a mutation was collected
by transbronchial lung biopsy.
Correlation between EGFR mutation status and patient
characteristics
Detection of EGFR mutations occurred significantly more fre-
quently in the serum DNA from the never-smokers (never-
smokers 5 out of 14 (35.7%); current/former smokers 2 out of 28
(7.1%); P¼0.031) (Table 4). Mutations were more frequently
detected in the DNA from tumour samples of never-smokers than
of current/former smokers (never-smokers 5 out of 14 (35.7%);
current/former smokers 3 out of 28 (10.7%); P¼0.092), but the
difference was not statistically significant. Mutations were detected
more frequently in the samples from females (tumour: females 5
out of 14 (35.7%), males 3 out of 28 (10.7%); serum: females 3 out
Table 1 Patient characteristics and EGFR mutation status
(n)













Squamous cell carcinoma 7 (16.7%)
Large-cell carcinoma 4 (9.5%)
Response to gefitinib
Partial response 10 (23.8%)
Stable disease 14 (33.3%)
Progressive disease 18 (42.9%)
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sof 14 (27.2%), males 4 out of 28 (14.3%)) and from patients with
adenocarcinoma (tumour: adenocarcinoma 7 out of 31 (22.6%),
non-adenocarcinoma 1 out of 11 (9.1%); serum: adenocarcinoma 6
out of 31 (19.4%), non-adenocarcinoma 1 out of 11 (9.1%)), but
the differences were not statistically significant. There were no
statistically significant differences in demographic characteristics
between the patients with EGFR deletion mutations and patients
with EGFR substitution mutations (data not shown).
Correlation between EGFR mutation status and response
to gefitinib
EGFR mutations were detected significantly more frequently in
responders to gefitinib. Seven of the nine patients with mutations
had a PR to gefitinib. Comparison between EGFR mutation status
and response to gefitinib showed that EGFR mutation was more
frequent in patients with a PR than in patients with SD/PD
(Table 4D).
EGFR mutations are associated with increased survival
The median PFS and OS of the patients treated with gefitinib was
60 days (95% CI, 52–68) and 228 days (95% CI, 150–306),
respectively. Patients with EGFR mutations in both tumour
samples and serum samples had a significantly longer median
PFS than the patients without EGFR mutations (194 vs 55 days,
P¼0.016, in tumour samples; 174 vs 58 days, P¼0.044, in serum
samples; Figure 1A). The patients with EGFR mutations had a
longer median OS than the patients without EGFR mutations, but
the difference was not statistically significant (716 vs 193 days,
P¼0.070, in tumour samples; 387 vs 228 days, P¼0.489, in serum
samples; Figure 1B). These results suggest that the patients who
were serum EGFR-mutation-positive had better outcomes of
gefitinib therapy in terms of PFS, OS, and response, than patients
who were EGFR-mutation-negative. In addition smoking status
(never-smoker vs former/current smoker) was found to be an
independent predictor of longer PFS (P¼0.002) and longer OS
(P¼0.035). Progression-free survival and OS were longer in female
patients and patients with adenocarcinoma than in male patients
and non-adenocarcinoma patients, respectively, but the differences
were not statistically significant.
DISCUSSION
We previously reported detecting EGFR mutations in serum DNA
by Scorpion ARMS method and that mutation status is useful for
predicting response to gefitinib (Kimura et al, 2006). The two
major findings in the present study provide additional support for
the use of serum DNA as an alternative to tumour samples for
detection of EGFR mutations in patients with advanced NSCLC.
First, these results demonstrate that EGFR mutation status in
serum DNA was the same as in tumour samples in almost every
patient. In addition, mutation status in serum DNA predicted for a
significantly greater response and time to progression with
gefitinib, as well as showing a trend towards increased OS in
patients treated with gefitinib. The results confirm the clinical
Table 2 Patients with EGFR mutation
EGFR mutation status
Age Gender Histology Stage Smoking Response Tumour tissue Serum
44 M Ad Re Never PR E746_A750del E746_A750del
79 M Ad IV Former PR L858R L858R
53 M Ad IV Never PR V689L, L858R
*
59 M La IV Current PD E746_A750del E746_A750del
63 F Ad IIIB Never PR L858R
62 F Ad IV Never PR E746_A750del E746_A750del
56 F Ad IV Never PR E746_A750del E746_A750del
57 F Ad IIIB Former SD E746_T751del
62 F Ad IV Never PR L858R L858R
Ad¼adenocarcinoma; del¼deletion; EGFR¼epidermal growth factor receptor; F¼female; La¼large-cell carcinoma; M¼male; PD¼progressive disease; PR¼partial
response; Re¼recurrence after surgery; SD¼stable disease. The numbering of the mutation sites was based on NP_005219.2 (amino acid). *L858R was detected both by
Scorpion ARMS and direct sequencing. V689L was detected by direct sequencing. All samples detected in serum DNA but the samples (*) were detected by Scorpion ARMS
alone.
Table 3 Sensitivity for detection of EGFR mutations in serum samples
Serum
+  
Tumour tissue + 6 2
  13 3
EGFR¼epidermal growth factor receptor; +¼mutation positive;  ¼mutation
negative.
Table 4 Frequency of EGFR mutations
Tumour tissue Serum
+   +  
(A) Gender and EGFR mutation status
Female 5 9 3 11
Male 3 25 P¼0.092 4 24 P¼0.669
(B) Histology and EGFR mutation status
Ad 7 24 6 25
Non-Ad 1 10 P¼0.657 1 10 P¼0.654
(C) Smoking habit and EGFR mutation status
Never 5 9 5 9
Current/former 3 25 P¼0.092 2 26 P¼0.031
(D) Response to gefitinib
PR 6 4 6 4
SD/PD 2 30 Po0.001 1 31 Po0.001
Ad¼adenocarcinoma; EGFR¼epidermal growth factor receptor; PD¼progressive
disease; PR¼partial response; SD¼stable disease; +¼mutation positive;
 ¼mutation negative. P-value: Fisher’s exact test.
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sreliability of EGFR mutation detection in serum DNA as a
predictive marker of response to gefitinib.
The sites of the EGFR mutations detected in this study are
identical to those reported in previous studies (Kosaka et al, 2004;
Pao et al, 2004). The majority mutations were in-frame deletions in
exon 19 and the missense mutation L858R in exon 21. The
comparison between mutation status and clinical manifestations in
this study confirmed the finding in previous studies that EGFR
mutations are frequently present in small subgroups of NSCLC
patients, including females, never-smokers, and patients with
adenocarcinoma histology, although these findings were not
statistically significant.
EGFR mutations were detected in only 1.0ml serum samples.
The amount of DNA extracted was minute, and its concentration
in roughly one-third of patients was below the minimum
concentration detectable by spectrophotometry. Moreover, lung
cancers are very heterogeneous, and patients’ serum also contains
DNA derived from normal cells. Direct sequencing seems unable to
provide satisfactory results for detection of EGFR mutations in
samples containing a mixture of mutated and wild-type DNA.
Although direct sequencing has generally been used to detect
EGFR mutations, detection by direct sequencing requires at least
30% of the DNA in the sample to be mutated (Bosari et al, 1995;
Fan et al, 2001). Small amounts and low percentages of mutated
DNA in serum can be missed by direct sequencings. When serum
is used as the material for detection of EGFR mutations, patients
with EGFR mutations may be diagnosed as having wild-type EGFR
because of the two limitations described above. In this study, the
mutation was detected by direct sequencing in only one patient.
The mutation status detected by Scorpion ARMS in serum samples
was nearly identical to that in tumour samples. The concentrations
of serum DNA in two of seven patients with EGFR mutations in
serum samples were below the minimum concentration detectable.
The high-sensitive method, Scorpion ARMS, completely resolved
the problem.
The mutation status in the pairs of samples from three patients
(3 out of 42, 7.1%) did not match. The results in the serum DNA of
two patients were mutation-negative, whereas mutations were
detected in actual tumour samples. The amount of tumour-specific
DNA may have been below the threshold of detection with the
Scorpion ARMS Kit in the patient with L858R. Little tumour-
specific DNA may be circulating in patients, and the quality of the
DNA is also a determinant of successful detection. Prolonged
storage of serum samples has been reported to result in a decrease
in the amount of DNA extracted (Sozzi et al, 2005). The other
patient had an E746_T751del, and the mutation was not detected
with the Scorpion ARMS in the patients. Although we have showed
the usefulness of Scorpion ARMS for detection of EGFR mutation
in serum samples (Kimura et al, 2006), Scorpion ARMS is only able
to detect mutations targeted by the Scorpion primers designed in
advance and in this study was capable of detecting the specific
mutation of E746_A750del in exon 19 and L858R in exon 21.
E747_P753del insS and L747_T751del are minor variations of
deletional mutations in exon 19 and were not detected by this
method in a preliminary experiment (data not shown). We do not
think that E746_T751del can be detected with Scorpion ARMS.
Mutation status in serum DNA was positive (V689L and L858R) in
one patient in whom no mutations were detected in actual tumour
samples. V689L and L858R are somatic mutations. We concluded
that the direct sequencing of DNA from the tumour sample yielded
the wrong result. Low rate of tumour-derived DNA in total DNA or
impure DNA extracted from tumour samples may have prevented
a detection of the mutation by direct sequencing.
On the basis of the results of this study, we conclude that it is
feasible to use serum DNA to detect EGFR mutation status and
evaluate its potential as a predictor of response to EGFR-TKI. The
serum assay to detect EGFR mutations circumvents the need for
tumour tissue and merits further validation of the use of serum
DNA to detect EGFR mutations as a predictor of response to, and
survival on gefitinib in prospective studies.











































































Figure 1 Kaplan–Meier probability of progression-free survival (A) and overall survival (B) with respect to the EGFR mutation status of NSCLC. P-values
were calculated by the log-rank test.
EGFR mutations in serum DNA
H Kimura et al
782





















Bosari S, Marchetti A, Buttitta F, Graziani D, Borsani G, Loda M, Bevilacqua
G, Coggi G (1995) Detection of p53 mutations by single-strand
conformation polymorphisms (SSCP) gel electrophoresis. A comparative
study of radioactive and nonradioactive silver-stained SSCP analysis.
Diagn Mol Pathol 4: 249–255
Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR,
O’Connell M, Shepherd FA, Johnson BE (2001) Twenty-two years of
phase III trials for patients with advanced non-small-cell lung cancer:
sobering results. J Clin Oncol 19: 1734–1742
Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey
C, Anker P (1996) Microsatellite alterations in plasma DNA of small cell
lung cancer patients. Nat Med 2: 1033–1035
Cuda G, Gallelli A, Nistico A, Tassone P, Barbieri V, Tagliaferri PS,
Costanzo FS, Tranfa CME, Venuta S (2000) Detection of microsatellite
instability and loss of heterozygosity in serum DNA of small and non-
small cell lung cancer patients: a tool for early diagnosis? Lung Cancer 30:
211–214
de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-
Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D,
Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R, On
behalf of the Spanish Lung Cancer, G (2006) Polymorphisms in DNA
repair genes modulate survival in cisplatin/gemcitabine-treated non-
small-cell lung cancer patients. Ann Oncol 17: 668–675
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman
JG (1999) Detection of aberrant promoter hypermethylation of tumor
suppressor genes in serum DNA from non-small cell lung cancer
patients. Cancer Res 59: 67–70
Fan X, Furnari FB, Cavenee WK, Castresana JS (2001) Non-isotopic silver-
stained SSCP is more sensitive than automated direct sequencing for the
detection of PTEN mutations in a mixture of DNA extracted from normal
and tumor cells. Int J Oncol 18: 1023–1026
Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA (2002) Epidermal
growth factor receptor family in lung cancer and premalignancy. Semin
Oncol 29: 3–14
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY,
Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda
K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP,
Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib
for previously treated patients with advanced non-small-cell lung cancer
(The IDEAL 1 Trial). J Clin Oncol 21: 2237–2246
Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim
DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK
(2005) Predictive and prognostic impact of epidermal growth factor
receptor mutation in non-small-cell lung cancer patients treated with
gefitinib. J Clin Oncol 23: 2493–2501
Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R,
Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J,
Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D,
Botwood N, Holloway B (2006) Molecular predictors of outcome with
gefitinib in a phase III placebo-controlled study in advanced non-small-
cell lung cancer. J Clin Oncol 24: 5034–5042
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD,
Knippers R (2001) DNA fragments in the blood plasma of cancer
patients: quantitations and evidence for their origin from apoptotic and
necrotic cells. Cancer Res 61: 1659–1665
Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM,
Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB,
Gandara DR (2001) Randomized phase III trial of paclitaxel plus
carboplatin versus vinorelbine plus cisplatin in the treatment of patients
with advanced non-small-cell lung cancer: a Southwest Oncology Group
trial. J Clin Oncol 19: 3210–3218
Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B,
Nishio K (2006) Detection of epidermal growth factor receptor mutations
in serum as a predictor of the response to gefitinib in patients with non-
small-cell lung cancer. Clin Cancer Res 12: 3915–3921
Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T
(2004) Mutations of the epidermal growth factor receptor gene in lung
cancer: biological and clinical implications. Cancer Res 64: 8919–8923
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum
of cancer patients and the effect of therapy. Cancer Res 37: 646–650
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan
BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani
DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-small-cell lung
cancer to gefitinib. N Engl J Med 350: 2129–2139
Nawroz H, Koch W, Anker P, Stroun M, Sidransky D (1996) Microsatellite
alterations in serum DNA of head and neck cancer patients. Nat Med 2:
1035–1037
Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N,
Smith JC, Markham AF (1989) Analysis of any point mutation in DNA.
The amplification refractory mutation system (ARMS). Nucleic Acids Res
17: 2503–2516
Nunes DN, Kowalski LP, Simpson AJG (2001) Circulating tumor-derived
DNA may permit the early diagnosis of head and neck squamous cell
carcinomas. Int J Cancer 92: 214–219
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye
FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers
WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung
cancer: correlation with clinical response to gefitinib therapy. Science
304: 1497–1500
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B,
Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M,
Varmus H (2004) EGF receptor gene mutations are common in lung
cancers from ‘‘never smokers’’ and are associated with sensitivity of
tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–
13311
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002.
CA Cancer J Clin 55: 74–108
Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de las Penas
R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F,
Catot S (2005) 14-3-3s methylation in pretreatment serum circulating
DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung
cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin
Oncol 23: 9105–9112
Sanchez-Cespedes M, Monzo M, Rosell R, Pifarre A, Calvo R, Lopez-
Cabrerizo MP, Astudillo I (1998) Detection of chromosome 3p alterations
in serum DNA of non-small-cell lung cancer patients. Ann Oncol 9:
113–116
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum
R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab
for non-small-cell lung cancer. N Engl J Med 355: 2542–2550
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J,
Johnson DH, The Eastern Cooperative Oncology Group (2002)
Comparison of four chemotherapy regimens for advanced non-small-
cell lung cancer. N Engl J Med 346: 92–98
Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba Fong
KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J,
Minna JD, Gazdar AF (2005) Clinical and biological features associated
with epidermal growth factor receptor gene mutations in lung cancers.
J Natl Cancer Inst 97: 339–346
Sozzi G, Conte D, Leon M, Cirincione R, Roz L, Ratcliffe C, Roz E, Cirenei
N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U (2003) Quantification of
free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol
21: 3902–3908
Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA,
Tavecchio L (2001) Analysis of circulating tumor DNA in plasma at
diagnosis and during follow-up of lung cancer patients. Cancer Res 61:
4675–4678
Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U (1999)
Detection of microsatellite alterations in plasma DNA of non-small cell
lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 5:
2689–2692
Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Verderio P, Pastorino U
(2005) Effects of prolonged storage of whole plasma or isolated plasma
DNA on the results of circulating DNA quantification assays. J Natl
Cancer Inst 97: 1848–1850
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel
J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005)
Gefitinib plus best supportive care in previously treated patients with
refractory advanced non-small-cell lung cancer: results from a rando-
mised, placebo-controlled, multicentre study (IRESSA survival evalua-
tion in lung cancer). Lancet 366: 1527–1537
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein
L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther
SG (2000) New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
EGFR mutations in serum DNA
H Kimura et al
783




















sNational Cancer Institute of the United States, National Cancer Institute
of Canada. J Natl Cancer Inst 92: 205–216
Travis W, Colby TV, Corrin B (1999) Histologic Typing of Tumors of Lung
and Pleura: World Health Organization International Classification of
Tumors (ed 3). Springer Verlag: New York, NY
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J,
Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha
Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M,
Ding K, Pater J, Shepherd FA (2005) Erlotinib in lung cancer –
molecular and clinical predictors of outcome. N Engl J Med 353:
133–144
Whitcombe D, Theaker J, Guy SP, Brown T, Little S (1999) Detection of
PCR products using self-probing amplicons and fluorescence. Nat
Biotechnol 17: 804–807
EGFR mutations in serum DNA
H Kimura et al
784
British Journal of Cancer (2007) 97(6), 778–784 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s